Hydromer, Inc. reported preliminary unaudited financial results for the quarter ended September 30, 2025, showing revenue of $0.91 million, representing an 11% increase compared to $0.81 million in the same period last year. The medical device coating technology company also reported net income of $53,000, marking a return to profitability after previous quarters of financial challenges.
The financial results are particularly significant given Hydromer's position as a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices with over 44 years of industry experience. According to CEO Michael Torti, the company maintains a high level of customer loyalty and is beginning to see growth from new customers entering its production coating line-up. This growth trajectory suggests potential stability in the medical device coating sector, which plays a critical role in improving patient outcomes through advanced medical device performance.
Hydromer's return to profitability during the third quarter indicates successful operational adjustments and strategic investments in infrastructure and equipment. The company continues to focus heavily on new product development while building what it describes as a scalable, innovation-driven platform. These developments matter because medical device coatings represent a crucial component in healthcare technology, affecting everything from surgical instruments to implantable devices that require specific surface properties to function effectively in biological environments.
The company also addressed challenges with its stock valuation and trading difficulties, noting plans to return HYDI to the OTCID Basic Market. This strategic move could potentially improve market accessibility and valuation for investors interested in the specialized medical technology sector. The announcement was made available through the original release on www.newmediawire.com.
For the medical device industry and healthcare sector broadly, Hydromer's financial improvement signals potential stability in the supply chain for advanced coating technologies. These coatings are essential for reducing complications in medical procedures, preventing blood clotting on devices, and inhibiting microbial growth that can lead to infections. The company's continued commitment to operational efficiency, customer partnerships, and next-generation technology development suggests ongoing innovation in a field that directly impacts patient safety and treatment outcomes.
The preliminary nature of these results means they remain subject to completion of the company's 2025 year-end financial reporting processes, reviews, audit, and potential adjustments. However, the positive trend demonstrated in these early figures provides insight into the recovery and strategic positioning of a long-established player in medical device surface modification technologies.
